Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BHAT - We are a premier gold trading and investment company headquartered in Hong Kong with operations in Shuibei, Shenzhen and Dubai. Established in 2010, our firm specializes in sourcing, refining, and trading high-quality gold. With a commitment to excellence and a robust network, Blue Hat. capitalizes on the strong market dynamics of Asia and the Middle East.
https://ir.bluehatgroup.com/
$NAHD Video Profile: Join Olenox Corp ($NAHD) as CEO Michael McLaren discusses Olenox Corp's groundbreaking tech that's reshaping the energy sector. Find out how they're transforming neglected oil and gas sites into sustainable assets, all while prioritizing both the environment and community well-being.
IGPK... THIS IS HUGE : Jun Fenghuang Group Experiencing Rapid Growth and Expansion... -- https://finance.yahoo.com/news/jun-fenghuang-group-experiencing-rapid-140000992.html
This is huge coming from the company:
The company is committed to consolidating all its divisions under one Jun Fenghuang Group, currently represented by the publicly traded OTC markets ticker IGPK, until the ticker is formally changed to JFHE.
JFH Digital E-Commerce Co., LTD is dedicated to listing on NASDAQ upon completing the merger of all its divisions.
Waiting on the name and symbol ticker to JFHE .......
Up 51% today because of NEWS PR released
$RJDG .0109 great earnings ps, revenue growth .0109 should be .06
$CYCA News: Cytta Corp Revolutionizes Public Safety With Four New Florida CyttaCOMMS Deployments In One Week
CyttaCOMMS In Active Trials With 54 Florida Law Enforcement Agencies With Over 600 Florida Direct Demo Requests Outstanding
LAS VEGAS, NV / ACCESSWIRE / July 26, 2024 / Cytta Corp (OTCQB:CYCA), the frontrunner in real-time video streaming technology and incident command software for public safety, is thrilled to announce the dynamic deployment of CyttaCOMMS 3.0 to four new law enforcement agencies in Florida: Temple Terrace PD, Plant City PD, Lake Placid PD, and Port St. Lucie PD last week.
Nationwide Expansion and Surging Interest
The buzz around CyttaCOMMS is undeniable, with free trials now active in 54 Florida law enforcement agencies and over 600 direct demo requests from Florida alone. This wave of interest highlights the pivotal role of CyttaCOMMS in revolutionizing public safety through state-of-the-art drone streaming technology.
This cutting-edge deployment is set to redefine public safety operations with secure, real-time video streaming and incident command features that significantly enhance drone capabilities. Our seamless integration across all drone brands is essential in the wake of Florida's statewide ban on DJI drones, ensuring these agencies remain at the forefront of technological advancement.
Unmatched Secure and Efficient Operations
CyttaCOMMS 3.0 provides unparalleled secure, low-latency video streaming, vital for real-time situational awareness. This transformative technology enhances coordination, response times, and operational efficiency during critical incidents.
Exciting Growth in CyttaAIR and CyttaCARES Initiatives
Our CyttaAIR program is soaring, with a second reselling group now established in Texas, showcasing our dedication to pioneering drone solutions. Moreover, our CyttaCARES initiative continues to be a cornerstone of our mission, focusing on community support and technological empowerment to boost safety and well-being.
About Cytta Corp
Cytta Corp (OTCQB:CYCA) is at the cutting edge of video streaming and communication solutions, driving innovation to enhance operational efficiency and public safety. Our flagship product, CyttaCOMMS, ensures secure, real-time video streaming across any drone brand, providing seamless integration and heightened situational awareness for law enforcement and emergency responders. Cytta's innovative new product, CyttaCARES , is a game-changer in ensuring the safety and well-being of children in educational institutions and beyond. CyttaAIR, a groundbreaking platform designed to innovate and consolidate the best of drone hardware, software, and resources for Federal and State Law Enforcement Agencies. Cytta's CyttaCOMP ISTAR (Intelligence, Surveillance, Target Acquisition and Reconnaissance) technology delivers real-time compression of video streams with ultra-low latency.
For more information about Cytta Corp and our groundbreaking technology solutions, please visit www.cytta.com.
Contact Us
Cytta Corp.
Toll free # : 1 877 CYTTAUS (298 8287)
Call Local : 1 740 CYTTAUS (298 8287)
http://www.cytta.com
info@cytta.com
Gary Campbell, CEO
Direct (702) 900-7022 (or message)
Gary@cytta.com
Natalia Sokolova, President & COO
Direct: (424) 333-0595 (or message)
Natalia@cytta.com
Mike Elliott, VP of Business Development
mikeelliott@cytta.com
(689) 222-8708.
SOURCE: Cytta Corp.
AFFL is Much-Much-Much Cheaper than NBRI now because buying NBRI at current price $0.0003 = buying AFFL at $0.0853 which is 2.4 Times of current price $0.0364!
Buying NBRI at last-July-high $0.0011 = buying AFFL at $0.3128 which is 7.82 Times of 52-week-high $0.04!
LOL, even buying NBRI at 52-week-low $0.0001 = buying AFFL at $0.0285 which is 14.3 Times of 52-week-low $0.0020!
LOL, even buying its OTC peer (FCCC has Record-High $41.3) at last-Friday-high $5.15 = buying AFFL at $13.1402 which is 408.1 Times of current Super-Ridiculous-Low price $0.0322! Which means Easy 408-Bagger Giant & Quick Rally here!
LOL, even buying its OTC-CI-tier peer (SSHT has Record-High $4.1) at this-June-high 0.95 = buying AFFL at $4.2522 which is 132.1 Times of current Super-Ridiculous-Low price $0.0322! Which means Easy 132-Bagger Giant & Quick Rally here!
Note, SSHT has -$54,256 Deeper Negative Net Asset or Shareholder's Equity Value v.s. AFFL only has -$33,935 Minor Negative Net Asset or Shareholder's Equity Value!
So, AFFL is Super Undervalued now!
AFFL is the Cheapest CLEAN-Shell with the Sought-After FIXED Super Tiny SS and Debt-FREE Excellent Financial Balance Sheet plus Only A Few Millions Shares Minor Float Available For Trading! Which means that this Diamond-In-Rough can Easily and Quickly soar Over 100-Bagger from here with just about A Couple Of Millions shares of Slapping-Volumes...
AFFL (only 24,554,116 shares OS now) is also at Hyper Oversold status based on its Record-High $6.00 (with 67,801,926 shares OS then)! Note, $6.00 x 67,801,926 = $16.568 x 24,554,116. So, the New Record-High for AFFL will be $16.568!
Its recent high $0.089 will be broken out in the coming days/weeks...
$CATV On The Brink Of Major Biotech Acquisition
https://www.degenmag.com/post/catv-on-the-brink?fbclid=IwZXh0bgNhZW0CMTEAAR3JeK6FnTkxWKrJ_DGdNQIetrmaeLVZWu95CgJQbUnn4-kVcxLqS6KRYKk_aem_4HuKAP7r6qqO5vYOWbQGtA
$GRNF - This transformation is led by the renowned CEO, Donald Steinberg, whose illustrious career in the marijuana sector spans over five decades.
https://finance.yahoo.com/news/grn-holding-corporation-announces-rebranding-120000766.html
$CYCA: Cytta Corp and FIZUAS Team Up to Enhance Drone and Streaming Tech for Law Enforcement: Cytta Corp. (Stock Symbol: CYCA)
June 25, 2024
Click here:
https://www.einpresswire.com/article/722643501/cytta-corp-and-fizuas-team-up-to-enhance-drone-and-streaming-tech-for-law-enforcement-cytta-corp-stock-symbol-cyca
From the article:
Technology Solutions Provider Addressing Various Industries for Integration, Streaming, Transfer and Storage of Video and Audio Data.
Partnered with FIZUAS Unmanned Aircraft Systems to Dominate the American Drone Reseller and Advanced Streaming Technology Market.
Launched Crisis Alert and Response Emergency System Mobile Application to Revolutionize School Safety.
Instant SOS Alert Automatically Triggers a Video Call That is Shared with All Emergency Responders Responsible for Protecting a School.
Initiative for Florida Law Enforcement Agencies Generates Overwhelming Response Amid New Drone Regulation Changes.
Strong Success for Groundbreaking AI-Enhanced Marketing Campaign in Florida.
Multiple Florida Police Departments and Sheriff's Offices Choosing CYCA CyttaCOMMS as their Drone Streaming Solution.
$AGBA News April 30, 2024
Building a Digital Economy Titan: AGBA and Triller Combine in $4 Billion Merger
https://finance.yahoo.com/news/building-digital-economy-titan-agba-130000244.html
$AVRW News: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results
New Initiatives Showing Encouraging Results
SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.
Key financial highlights for the fourth quarter included the following:
Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.
Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.
Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.
Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.
Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.
"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.
Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.
Operational Highlights
Other operational highlights during the fourth quarter of 2023 included:
Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/
About Avenir Wellness Solutions, Inc.
Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: www.avenirwellness.com.
About The Sera Labs, Inc.
Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.
CONTACTS:
Investor Relations
Hanover International Inc.
T: (760) 564-7400
E: investor@avenirwellness.com
PLANTX Life 1 year forecast $3.5310, a +17082.70%
increase from the current price of $0.0206.
https://stockscan.io/stocks/PLTXF/forecast
https://vegainvestors.com/
https://investorshub.advfn.com/PlantX-Life-Inc-VEGA-38643
IGPK.... Yield is GONE. 🚀🚀 Now the 1st quarter will be filed like any moment now... today would be that best time to grab some shares before the quarterly is filed... This week Dark defunct was removed, Grace period removed , Â Annual Report filed, Attorney letter, updated attorney letter. Today the yield sign is gone...
$AVRW: Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our unique and proprietary skin care formulations. With 15 patents under our control, the highly positive reviews Seratopical DNA Complex is receiving, and more new products in development, 2024 is set up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward.
Sincerely,
Nancy Duitch, CEO
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$NBRI take a minute and check it out. It will be worth it.
PLANTX NO RESISTANCE; Key Turning Points -
3rd Resistance Point 0.0250
2nd Resistance Point 0.0250
1st Resistance Point 0.0250
https://investorshub.advfn.com/PlantX-Life-Inc-VEGA-38643
Trades on both CSE and OTC
$PDGO - The recent acquisition underscores Paradigm Oil & Gas, Inc.'s commitment to growth and diversification within the energy sector. By acquiring key assets and stakes in established players, the company seeks to leverage synergies, drive operational efficiencies, and capitalize on emerging opportunities in the oil and gas market.
https://www.otcmarkets.com/stock/pdgo/news/Paradigm-Oil--Gas-Inc-PDGO-Expands-Market-Presence-with-Proposed-Strategic-Oil-and-Gas-Acquisitions?id=439005
$WRIT - The Company has begun talks with other esports and gaming companies to provide enhanced rewards, NFTs, and custom digital awards packages to amplify the competitive gaming experience. With a focus on competitions, live tournament event services, and digital collectibles and awards, the Amiga Games brand is poised to be a leader in the gaming industry.
https://www.otcmarkets.com/stock/WRIT/news/New-Era-in-Blockchain-Gaming-Writ-Media-Group-Inc-Announces-Launch-of-Revolutionary-NFT-Minting-Engine-to-Transform-Espo?id=437361
$AGBA Triller going to see ‘biggest influx’ of users after new TikTok law:
https://www.foxbusiness.com/video/6351757905112
$PNPNF - Diverse and Strategic Asset Portfolio
Beyond the Nisk project, Power Nickel Inc. holds significant land packages in British Columbia and Chile, including the 100% acquisition of the Golden Ivan project in the prolific Golden Triangle. Additionally, the company's ownership of a 3-percent NSR royalty interest in the Copaquire copper-molybdenum deposit further diversifies its asset base, offering a broad spectrum of mineral exploration and development opportunities.
https://reports.stocknewstrends.com/facing-a-20x-surge-in-demand-this-hidden-gem-could-be-sitting-on-a-potential-billion-dollar-nickel-deposit?utm_source=corporateads&utm_medium=affiliate&utm_campaign=pnpnf_us&utm_id=pnpnf_us
$AGBA 🛫🛫MERGER NEWS EXPLODING! #SHORTSQUEEZE
GREAT YOU TUBE VIDEO!
$FRGGF - Experienced Management Team
Led by President Lorne Warner and with the recent appointment of industry expert Matt Warder as Strategic Advisor, Forge Resources Corp. (OTCQB: FRGGF) (CSE: FRG) boasts a seasoned management team with diverse expertise in exploration, development, and strategic planning, enhancing its ability to capitalize on opportunities and navigate the complexities of the mining sector.
https://reports.stocknewstrends.com/hidden-gems-breakthroughpositive-drill-results-emerge-in-one-of-the-worlds-largest-underdeveloped-gold-copper-deposits?utm_source=corporateads&utm_medium=affiliate&utm_campaign=frggf_us&utm_id=frggf_us
$AGBA Article April 22, 2024
BKFC owners at Triller acquired by Hong Kong-based finance company in $4 billion merger
https://www.mmafighting.com/2024/4/22/24137378/bkfc-owners-at-triller-acquired-by-hong-kong-based-finance-company-in-4-billion-merger
$PDGO - In connection with the previously announced change in control, the new management of PDGO has commenced the process of identifying and initiating targeted acquisitions for PDGO.
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-and-Gas-Inc-announces-its-plans-going-forward?id=436241
$GDHG - With a diverse portfolio of amusement and theme parks across China, GDHG is venturing to launch in Indonesia and is positioned to capture the global market's sector, offering investors an unparalleled growth opportunity. https://goldenheavengroup.gcs-web.com/news-releases/news-release-details/golden-heaven-group-holdings-ltd-expand-indonesia-market-its… $DIS $SEAS $SIX $FUN $CMCSA
$GDHG - With a diverse portfolio of amusement and theme parks across China, GDHG is venturing to launch in Indonesia and is positioned to capture the global market's sector, offering investors an unparalleled growth opportunity. https://t.co/orjysKZ7Pm $DIS $SEAS $SIX $FUN $CMCSA pic.twitter.com/NX40gcWqPy
— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) April 23, 2024
$IZM grabbing it as longest it is below $5 should pay out bigtime imo.
IGPK.... You don't own this stock? You should......
FROM the company yesterday:
Integrated Cannabis Solutions
OTC Update 4-17-24
JFH Digital E-Commerce would like to share recent developments that have caused a delay in posting the 2023 Annual Report and First Quarter 2024 Report.
We filed with the State of Nevada to officially change our name to reflect our current operations. Our counsel has been working to gain access to upload our reports to OTC to remove the Yield sign and allow us to proceed with FINRA to change our name and ticker.
OTC has a new procedure. They will not allow a company access when they have filed to change their name at the State level until FINRA has approved the change. This is a process that can take several months to complete.
To expedite matters and avoid any further delays in removing the Yield, we will change the name back to Integrated Cannabis Solutions, Inc., with the State of Nevada. Once changed, we will be granted access to upload our financials, remove the Yield sign, and restore confidence in the market.
Thank you for your continued support during this process.
JFH Digital E-Commerce
$AGBA - The private placement was particularly noteworthy as it was executed at a price significantly above the market price of AGBA ordinary shares.
https://finance.yahoo.com/news/agba-celebrates-major-milestone-successful-140000317.html
$PDGO News April 09, 2024
Paradigm Oil and Gas, Inc. announces its plans going forward.
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-and-Gas-Inc-announces-its-plans-going-forward?id=436241
$AURI News April 12, 2024
Auri Launches a National Wholesale Portal for Re-Sellers With a New Product
https://finance.yahoo.com/news/auri-launches-national-wholesale-portal-123000296.html
OTC: $TREIF CSE: $TRUE -- THE WORLD’S MOST INTELLIGENT, PERSONALIZED HEALTHCARE AI ENGINE https://treatment.com/investors/
$TREIF Keep on watch!!! hearing a huge update coming very soon....
$PDGO - Phase I Operations, Inc., now holds 100% of the issued and outstanding Series A Preferred Shares, representing the controlling stake in the Company.
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-And-Gas-Inc-Announces-Change-in-Control-and-Letter-of-Intent?id=425854
$NRXP News: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend
-- 50% reduction in corporate overhead and 25% reduction in overall net loss in 2023, compared to 2024 with $0.20 per share improvement in negative earnings. Additions to working capital of $8 million in Q1 2024.
-- Company forecasts first commercial revenue in 2024 from sales of ketamine and related technologies. Company received advance of first milestone payments in 2024 for ongoing development of NRX-101 from Alvogen and Lotus Pharmaceuticals, Inc. (1975.TW)
-- Company announces new partnership around the first drug to potentially modify the underlying cause of schizophrenia
-- Data lock this week and top-line data expected this month, after completed enrollment of the Phase 2b/3 trial of NRX-101 in Treatment Resistant Bipolar Depression (TRBD); trial demonstrated 94% rater concordance, far in excess of industry norms and exceeded industry norms in medication compliance
-- Two new Investigational New Drug applications (INDs) accepted by the US Food and Drug Administration (FDA) for NRX-101 in Chronic Pain and Complicated UTI.
-- Data lock expected this week in 200-person DOD-funded trial of D-cycloserine (DCS), the key component of NRX-101, to treat chronic pain, conducted by Northwestern University
-- Grant of Qualified Infectious Disease Product (QIDP), Fast Track and Priority Review designations for NRX-101 in the treatment of Complicated Urinary Tract Infection (cUTI); Publication last week of QIDP-qualifying data in a peer-reviewed journal. NRx is reviewing partnership options
-- Established HOPE Therapeutics to develop and launch IV Ketamine together with related technologies with FDA New Drug Application to be submitted this year. In advance of FDA approval, HOPE is partnered with national 503b and 503a pharmacies to address the ketamine shortage declared by FDA. HOPE is planned to be spun out as a separate company to be owned by NRx, current NRx shareholders via a tax-free dividend, and new investors; Term Sheets received from prospective anchor investors for $60 million of new investment, once publicly listed
-- HOPE is presenting data from four randomized, prospective trials demonstrating safety and efficacy in 800 patients of IV Ketamine in treating severe and suicidal depression as the clinical basis for New Drug Application (NDA) for HTX-100 (IV Ketamine); expecting stability and CMC data sufficient for NDA filing by June 2024.
-- Added over $8 million in working capital, including an advance of a $5.1 million milestone payment from partners Alvogen, Inc. and Lotus Pharmaceuticals
-- Elected nationally recognized attorney in highly regulated industries, and healthcare specialist, Janet Rehnquist, Esq., to the Company's Board of Directors
-- Management has taken actions to address NASDAQ listing compliance and naked shorting of NRx securities
-- Management to host a conference call, April 1, 2024, at 8:30 AM ET
RADNOR, Pa., April 1, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year ended December 31, 2023 and provided a business update.
"2023 was a pivotal year for NRx in which we advanced from a single clinical trial in a single indication to a dramatically streamline its operations with a 50% reduction in overhead costs, a 25% reduction in overall costs, and a $0.20 per share improvement in negative earnings, while completing our clinical trial objectives. We expect data from two key trials this month and predict our first commercial revenue by the end of 2024. Over the past year the Company has navigated the most challenging business environment in the history of the biotechnology industry. Despite unprecedented headwinds, we negotiated a critical commercial partnership for our lead compound in bipolar depression, while retaining rights to the far larger indications of chronic pain and PTSD," said Stephen Willard, J.D., Chief Executive Officer and Director of NRx Pharmaceuticals. "We augmented our intellectual property portfolio to include the use of our lead compound in chronic pain and anticipate results of a 200-person efficacy trial that could open a multibillion dollar opportunity in this therapeutic area. We have acquired sufficient data on safety and efficacy of ketamine to support a New Drug Application for IV ketamine in acute suicidality. We established the foundation of a specialty pharmaceutical business around ketamine that we expect to yield positive cash flow by the end of 2024. Finally, we received unanticipated data supporting the use of our lead compound to treat complicated Urinary Tract Infection and Pyelonephritis, a condition that affects 3 million Americans and results in more than 15,000 deaths annually. We believe that NRx is poised for substantial growth in 2024 and look forward sharing further results in our conference call."
Fourth Quarter Clinical, Regulatory and Corporate Highlights
Development of NRX-101 for Treatment-Resistant Suicidal Bipolar Depression
The Company has announced today that it expects data lock this week and release of top line data this month in its Phase 2b/3 trial of NRX-101 in Suicidal Bipolar Depression. In 2023, the Company published results of a phase 2 trial demonstrating that oral NRX-101 extends the effect of IV ketamine in reducing both suicidality and depression in patients presenting to the hospital. This trial is designed to determine whether oral NRX-101 can reduce depression and suicidality in outpatients, which would be a massive broadening of the potential market for the drug. This potential expansion was guided by the Company's January 2023 meeting with the FDA in which NRx was advised to seek approval for NRX-101 as a drug for bipolar depression as a chronic, intermittent disease, a far broader indication.
With the completion of data collection, an unprecedented data integrity standard (94% agreement between site raters and central raters) has been achieved across the completed cohort of patients.
In 2023, the Company completed manufacture and Chemical Manufacturing Controls for NRX-101. This initiative is expected to yield stability data sufficient to support a shelf life in excess of two years at time of potential drug launch (should the clinical trials be successful). The completion of this manufacturing milestone allowed the Company to decrease its ongoing expenditure associated with manufacturing and development of chemical manufacturing controls.
During Q4 and in early 2024, the Company has continued to solidify its working relationship with Alvogen and Lotus, and begun working in unison to plan the final development and commercialization of NRX-101. These partners recently advanced $5 million of the first milestone to the Company. As previously announced, a successful readout from this trial and FDA interaction will trigger an additional $4 million milestone payment together with transfer of future development costs to our partner. The partnership provides for potential milestones of $329 million and a royalty reaching 15% on Net Sales.
NRX-101 for Treatment of Chronic Pain:
The Company has previously detailed the scientific basis for treatment of chronic pain with DCS as outlined in a 2016 scientific paper published by Schnitzer, et. al. and in the White Paper posted by the Company's Scientific Leadership (Sappko, et. al.). In 2023, the Company licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain.
Chronic pain affects more than 50 million American adults, compared to the approximately 3 million who report thoughts of suicide on an annual basis. There has been no new non-opioid class of drugs to treat nociceptive pain in the past two decades and NRX-101 has the potential to be the first N-methyl-D-aspartate (NMDA)-antagonist drug to seek approval for this indication. Today, ketamine is used off label to treat nociceptive pain, despite its clear limitations (addiction, neurotoxicity, hallucination, and the need for IV administration.)
The Company is advised that data lock will occur this week in a 200-person randomized prospective trial funded by the US DOD (NCT 03535688) in which patients with chronic pain were randomly assigned to DCS 400mg/day vs. placebo. Top line results will follow. Should these results support efficacy of DCS in the treatment of chronic low back pain, they are expected to provide a Breakthrough Therapy path towards treatment of chronic pain with DCS and DCS-containing medicines.
Spin out of HOPE Therapeutics and progress towards an NDA for NRX-100 (ketamine) in the treatment of suicidal depression.
When NRx met with the FDA in January 2023, the agency strongly encouraged the Company to develop NRX-100 (IV Ketamine) as a labeled drug, rather than rely on prior stabilization of suicidality and depression achieved via the common clinical practice of infusing generic ketamine compounded in licensed pharmacies. Shortly thereafter, the FDA issued the first of two advisory letters warning physicians against using compounded forms of ketamine and began a program of rigorous inspections of such pharmacies. Although there was once an expectation that intranasal administration of ketamine would be effective in treating suicidality, the attempts to demonstrate the clinical efficacy of nasal racemic ketamine for acute suicidality have not succeeded.
Accordingly, in Q3 the Company finalized a scientific collaboration with Prof. Marion Leboyer of Paris, France and Prof. Mocrane Abbar of Lyon, France in order to incorporate the results of a 156-person inpatient trial of intravenous ketamine vs. placebo for the stabilization of patients admitted for acute suicidality (the KETIS trial). The findings of the trial demonstrate a statistically significant reduction in both suicidality (the primary endpoint) and depression (the secondary endpoint) among patients treated with intravenous ketamine compared to those treated with placebo. (Link)
In the fourth quarter, the company similarly licensed data from Columbia University. In this trial, Dr. Michael Grunebaum and colleagues demonstrated a rapid and statistically significant reduction in Suicidal Ideation (SSI) at day 1 (p=0.0003) and in depression (P=0.0234), as measured by the Profile of Mood States (POMS) among patients randomized to IV Ketamine compared to those randomized to midazolam. This trial was published in the American Journal of Psychiatry https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880701/.
The patient-level deidentified data from both studies have now been received by the Company and are being assembled in the electronic format required by the FDA. The Company believes that these randomized, blinded prospective trials encompassing nearly 240 participants, when submitted for review at a patient level could be sufficient to demonstrate preliminary safety and efficacy of intravenous ketamine in acutely suicidal patients. Data are expected to be transmitted to FDA by the end of 2Q23.
Submission of an NDA for the use of IV Ketamine is dependent upon submission of a manufacturing file documenting the manufacture of a presentation of ketamine suitable for single-patient use in the treatment of suicidal depression. In November 2023, the Company initiated manufacture of ketamine together with Nephron Pharmaceuticals, Inc. (West Columbia, SC) to develop a single patient presentation of ketamine. This formulation is expected to overcome some of the formulation deficiencies of existing forms of ketamine (developed for anesthesia) and is expected to have diversion-resistant and tamper-resistant features.
On March 30, 2024, the Company booked first commercial delivery of ketamine manufactured to 503b pharmacy standards from Nephron. HOPE will be distributing this presentation to qualified ketamine clinics in coordination with Nephron under Nephron's 503b pharmacy license in light of the current FDA-declared drug shortage of ketamine, starting this month (April 2024).
Treatment of Urinary Tract Infection (UTI) and Urosepsis:
Although treatment of UTI is quite different from use of NRX-101 to treat Central Nervous System disorders, D-cycloserine was originally developed as an antibiotic because of its role in disrupting the cell wall of certain pathogens. This is true of a number of drugs used in psychiatry today. D-cycloserine fell out of favor as an antibiotic in the 1970s because of the CNS effects caused by its NMDA-blocking properties and because of the widespread availability of effective first and second-generation antibiotics.
During Q3 2023, NRx tested NRX-101 and its components against resistant pathogens that appear on the Congressionally-mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRx was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA.
In recent years, increased antibiotic resistance to common pathogens that cause urinary tract infections and urosepsis (i.e., sepsis originating in the urinary tract) has resulted in a marked increase in cUTI, hospitalization, and death from urosepsis. The US Center for Disease Control and Prevention reports that more than 1.7 million Americans contract sepsis each year, of whom at least 350,000 die during their hospitalization or are discharged to hospice (CDC Sepsis Ref.). There are approximately 3 million patients per year who contract cUTI in the US annually (Lodise, et. al.). Additionally, should NRX-101 succeed in clinical trials, the Company will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.
Qualification for QIDP affords a sponsor five years of additional market exclusivity from FDA, regardless of patent status.
The Company does not anticipate funding this initiative with core NRx assets and is exploring structures for partnership opportunities. Should the Company or its partners succeed in serving 10% of the cUTI market, the Company believes that the revenue from NRX-101 has the potential to hundreds of million annually, based on 3 million cases per year (Lodise, et. al.) in the US and potential pricing of over $3,500/course of therapy.
Cash runway and financing
The Company continues to believe cash on hand is sufficient to fund operations through potential delivery of the upcoming milestones described herein.
Financial Results for the Quarter and Year Ended December 31, 2023
For the three months ended December 31, 2023, we at NRx Pharmaceuticals reduced our net loss from $10.2 million in the final quarter of 2022 to $4.3 million in 2023, representing nearly a 60% improvement year over year. For that same period, we reduced research and development expenses from $4.5 million in 2022 to $2.5 million in 2023, while substantially improving and finalizing our clinical trial enrollment. The $2.0 million decrease is related primarily to a decrease of $1.1 million in clinical trial expenses, $0.6 million in stock-based compensation, and $0.2 million in consulting and personnel wage costs. Also in that 3 month period we recorded a 67% reduction in general and administrative expenses, from $5.4 million in 2022 to $1.8 million in 2023. The decrease of $3.6 million is related primarily to a decrease of $1.3 million in insurance expenses, $1.3 million in stock-based compensation, $0.5 million in employee expenses, $0.2 million in legal and professional consulting fees, and $0.2 million in franchise tax expenses.
For the year ended December 31, 2023, NRx Pharmaceuticals reduced its net loss to $30.2 million compared to $39.8 million in the prior year. These efficiencies represent an improvement in net loss of nearly $10.0 million year over and a 20 cent, or 34%, improvement in net loss per share year over year. Over that annual period we recorded $13.4 million of research and development expenses compared to $17.0 million for the same period in 2022 representing a 21% decrease year over year. The decrease of $3.6 is related primarily to a decrease of $2.1 million in clinical trial and development expenses, $0.9 million related to fees paid to regulatory and process development consultants, $0.8 million in stock-based compensation while offset by a $0.2 million increase in patent costs as our patent portfolio has expanded.
Please note that the improvement in G&A expenses is even larger than the improvement in other areas. We decreased G&A by $13.1 million, from $27.3 million in 2022 to $14.2 million in 2023, nearly a 50% decrease year over year.
As of December 31, 2023, we had $4.6 million in cash and cash equivalents. Over the first three months of 2024 we improved our access to working capital by $8 million total, representing $2.9 million from equity sales and $5.1 million from the Alvogen milestone advance, while reducing our corporate indebtedness by 50% as shown in our financial statements.
We continue to implement operational efficiencies to extend runway and focus on our path to generating revenue. We believe that the near-term delivery of clinical trial data and the planned the launch of HOPE Therapeutics will be defining events in the second quarter of 2024.
Conference Call and Webcast Details
A live webcast of the conference call will be available on the Company's website at 8:30 a.m. ET today, at https://ir.nrxpharma.com/events. An archive of the webcast will be available on the Company's website for 30 days. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-877-704-4453 or internationally 1-201-389-0920.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL76439&sd=2024-04-01 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-update-302104468.html
SOURCE NRx Pharmaceuticals, Inc.
$NRXP News: NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
RADNOR, Pa., March 25, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present at the Ketamine 2024 Conference, which is planned for March 25-27, 2024, at the Blavatnik School of Government in Oxford, UK.
The Ketamine 2024 Conference assembles many of the top scientists and clinicians in the field from around the world and is a forum for top researchers and experienced and interested clinicians to learn from each other about the therapeutic use of Ketamine and related compounds for affective disorders. Dr. Javitt will present a keynote talk titled, "Ketamine: the Efficacy is Clear, Approval is Critical, and the Risks Must be Balanced." He will present an overview of the rapid and dramatic efficacy of Ketamine in the treatment of acute suicidality as well as recent science documenting the potential for neurotoxicity with long-term CNS side effects if ketamine is used without appropriate safety controls as a long-term drug.
"HOPE Therapeutics builds upon four decades of scientific discovery related to the role of the brain's NMDA receptor and the effects of ketamine and other NMDA-antagonist drugs in rapidly attenuating symptoms of depression and suicidality. It is an honor for our company to be invited to share a platform with those who have established this field of science and who may forever change the outlook and future path of patients who suffer from suicidal depression and PTSD," said Dr. Javitt.
Ketamine 2024 Conference Presentation
When: Monday, March 25th, 2024
Time: 1:40-2:00 PM GMT
Title: Ketamine: The Efficacy is Clear, Approval is Critical, and the Risks Must be Balanced
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders
March 18, 2024
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-123000925.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
$AVRW - Dr. Persky will also advise along with Rob Davidson on formulating the brand's future plant-based, cruelty-free and scientifically grounded products.
$EPAZ - Following a successful collaboration with the US Air Force in SBIR Award Phase 1, ZenaDrone has gained significant traction in acquiring additional contracts. SBIR Phase 2 funding aims to continue the research and development.
$GDHG - The Board has determined that the Share Repurchase Program is in the best interest of the Company's shareholders based on its analysis and estimation that the current share price is significantly lower than the intrinsic value and that the Share Repurchase Program may improve shareholders' confidence in the Company.
https://finance.yahoo.com/news/golden-heaven-group-holdings-ltd-130000712.html
$RENB - GEDi Cube's partnership with NVIDIA to expand its multiomic capabilities to multimodal; and consistently achieving "the holy grail of cancer research" in preclinical studies.
https://finance.yahoo.com/news/renovaro-biosciences-releases-ceo-shareholder-143000252.html
$BNNHF About Benjamin Hill Mining Corp.
Benjamin Hill Mining Corp. is a Canadian-listed junior exploration company focused on exploring and advancing the Alotta project, a prospective porphyry copper-gold-molybdenum project located 50 km south of the Casino porphyry deposit in the unglaciated portion of the Dawson Range porphyry/epithermal belt in the Yukon Territory of Canada.
In addition, the Company holds a 20% interest in Aion Mining Corp., a company that is developing the fully permitted La Estrella coal project in Santander, Colombia. The project contains eight known seams of metallurgical and thermal coal.
$AVRW is set for a high growth sales and revenue year in 2024 based on all the positive groundwork that has been laid to date. The company's Seratopoical Revolution brand has clearly been demonstrated as top quality in terms of its formulations and performance, especially with the very high level endorsements that have been presented.
$AVRW Feature: Media Grabbing Seratopical Revolution Skin Care Line, Personal Choice of Nicole Kidman for Years, Now Directly Recommended by LeadingLA Plastic Surgeon for Superior Anti-Aging Results
https://news.columbusnewsonline.com/story/478529/media-grabbing-seratopical-revolution-skin-care-line-personal-choice-of-nicole-kidman-for-years-now-directly-recommended-by-leadingla-plastic-surgeon-for-superior-antiaging-results-avrw.html?utm_source=dlvr.it&utm_medium=twitter
From this article:
– Proprietary Nutraceutical & Topical Delivery Systems for Wellness and Anti-Aging Beauty Product Lines.
– Company Currently Holds 15 Patents.
– Seratopical Revolution Skin Care Products are Promoted by the Company’s Global Brand Ambassador and Strategic Partner Nicole Kidman.
– LA-Based Facial Plastic Surgeon Dr. Michael Persky Directly Supporting Latest Seratopical DNA Complex Product.
– Media Exposure in Top-Tier Publications Including CNN Underscored, Page Six, PEOPLE Magazine, and More.
– Q3 Net Revenue Increased Sequentially from Q2 2023.
– Sales Expected to Increase Significantly During Q4 and Into 2024.
– Gross Margin Increased 80 Basis Points Quarter-to-Quarter with Further Expansion Expected in Q4.
– Upcoming Launch of New Beauty Product Releases &New Marketing Initiatives.
– Latest Sales Results Show Accelerating Strength via New Marketing Campaigns
🎉 Big AI News Out! 🎉
The Kinetic Group (OTC: KNIT) www.knitgrp.com has acquired 100% of US based BINNOPS US TECHNOLOGIES INC in an all-stock transaction. Binnops is a leading provider of profitable artificial intelligence software solutions to enterprises in the energy, manufacturing, transportation, aeronautical, retail, and government sectors.
The acquisition positions KNIT as a leading provider of Digital Twins, Smart Assets, AI predictive analytics, and Metaverse engagement to enterprises and retail clients. Delivering transformative digital technologies since 2016, Binnops has provided customizable solutions to leading Fortune 500 companies, across the globe, with lifetime contract revenue of over six million dollars. As a result, KNIT acquires a robust portfolio of clients, spanning the globe, and a pipeline of business opportunities. With expected sales of US$5.1M and EBITDA of US$2.8M, in the first year after the acquisition, Binnops' smart asset solutions drive real digital transformation solutions that enhance an enterprises' margins by increasing efficiency and productivity and managing risk through predictive analytics. KNIT can go beyond the hype and deliver real results.
Ana María Méndez, Founder and Chairwoman of KNIT said "We recognize the need for enterprises to embark on their digital transformation journey and with this acquisition KNIT is the perfect partner to go on this journey. We also recognize the outstanding management team that has taken Binnops this far and are certain that the acquisition will only enhance the team's capabilities." We are committed to KNIT's expansion and increasing its market share in the AI space. We also expect to uplist to the OTCQB market in the near term".
KNIT hired CIM Securities LLC as lead placement agent in a $3 million raise structured as an 8% PIK Dividend Series A Convertible Participating Preferred. The preferred offers a 1.5x liquidation preference and is priced at $1.00 per preferred share. Use of funds is to promote international sales and rollout a subscription-based revenue model.
CIM Securities is an investment banking and venture capital firm for growing middle market companies. CIM Securities is headquartered in Centenial, Colorado
Read more: https://bit.ly/News_KineticGroupInc
Press "Pending" add it to your #StockWatchList. $RDAR On Watch for News!! RaadrInc.
Read more: https://raadr.com/
Known as the internet anti-bullying company, $RDAR RAADR, Inc.
publishes software that keeps kids safe online and on social media.
RAADR's products enable kids, parents, school districts, and law enforcement to keep an eye out for
bullying and other dangerous activity occurring in real-time on social media and in the metaverse.
The RAADR 2.0 parental monitoring and reporting application is available for download.
IOS APPLE LINK: https://apps.apple.com/us/app/raadr/id1661624979
GOOGLE PLAY ANDROID LINK: https://play.google.com/store/apps/details?id=com.raadr
$TMGI Insider Activity
https://www.nasdaq.com/market-activity/stocks/tmgi/insider-activity
$BMNR InvestorBrandMedia Article December 06, 2023
InvestorBrandMedia: Bitmine Immersion Technologies (BMNR) Leads the Way in Advanced Bitcoin Mining with Innovative Immersion Tech
https://www.marketscreener.com/quote/stock/CO...-45510623/
💲$BLEG .0015 Branded Legacy strengthens financial stability with a new line of credit and commits to enhancing shareholder value by avoiding a reverse stock split.
https://www.prnewswire.com/news-releases/branded-legacy-inc-secures-1m-line-of-credit-affirms-no-reverse-split-and-previews-upcoming-investor-engagements-301980129.html
Followers
|
2670
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
304055
|
Created
|
06/18/09
|
Type
|
Free
|
Moderator HotStockAce | |||
Assistants |
AMWI= .20 to $1.39 Over 500% GAINS! LEXG= $1.00 Call. Ran to $13.00. 1,300% GAINS! RYUN= .30 to $2.50. 700% GAINS! POTG= .20 Call. Ran to $1.28! Over 500% GAINS! SRSR= .01 to .20! 2000% GAINS!
AMWI= .20 to $1.39 Over 500% GAINS! LEXG= $1.00 Call. Ran to $13.00. 1,300% GAINS! RYUN= .30 to $2.50. 700% GAINS! POTG= .20 Call. Ran to $1.28! Over 500% GAINS! SRSR= .01 to .20! 2000% GAINS!
TIME TO MAKE SOME $$$$
AMWI= .20 to $1.39 Over 500% GAINS! LEXG= $1.00 Call. Ran to $13.00. 1,300% GAINS! RYUN= .30 to $2.50. 700% GAINS! POTG= .20 Call. Ran to $1.28! Over 500% GAINS! SRSR= .01 to .20! 2000% GAINS!
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |